Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Rheumatology (Oxford, England)|February 8, 2018
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritisMark C Genovese, Joel M Kremer, Cynthia E Kartman, et al.
Clinical and Experimental Rheumatology|April 27, 2019
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)Thomas Dörner, Hendrik Schulze-Koops, Gerd-Rüdiger Burmester, et al.
European Journal of Dermatology : EJD|December 3, 2019
Memory CD4+ T cells lacking expression of CCR7 promote pro-inflammatory cytokine production in patients with diffuse cutaneous systemic sclerosisGiovanni Almanzar, Marc Schmalzing, Matthias Klein, et al.
Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Arthritis Research & Therapy|April 19, 2015
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trialJoel M Kremer, Alan J Kivitz, Jesus A Simon-Campos, et al.
Rheumatology (Oxford, England)|March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
Plos One|May 29, 2019
New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II studyMatthias Englbrecht, Rieke Alten, Martin Aringer, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic DiseaseMatthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trialNils Venhoff, Wolfgang A Schmidt, Raoul Bergner, et al.
Arthritis Care & Research|August 3, 2016
Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated ChallengeMatthias Englbrecht, Rieke Alten, Martin Aringer, et al.
Pageof 11